- Teva Pharmaceutical Industries (TEVA -1.4%) inks a collaborative research agreement with privately held Vancouver, BC-based AbCellera to discover rare monoclonal antibodies via its high-throughput single cell antibody platform.
- Under the terms of the partnership, AbCellera will receive an upfront payment, research funding and antibody development-related milestones. Specific financial terms are not disclosed.
Teva teams up with AbCellera in antibody discovery
Recommended For You
More Trending News
About TEVA Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| TEVA | - | - |
| Teva Pharmaceutical Industries Limited | ||